Pan-cancer Recurrence monitoring

SeekInClarity^TM is the first-in-class blood-based pan-cancer treatment response monitoring test. It is a 10ml peripheral blood-based test which uses a cutting edge multivariable cancer recurrence index (molecular tumor burden)model，in conjunction with shallow WGS of cfDNA and a set of specific plasma protein markers detection. MRI model maps the panoramic cancer genome by sWGS data, predicts tumor burden and therapeutic efficacy of the late-stage cancer patients during treatment (including chemotherapy、target therapy and immunotherapy or combined therapy) by evaluating the copy number aberration (CNA) and fragment size (FS)，and combinating with 7 plasma protein markers.

Indicated subjects: Late-stage cancer patients
Sample requirement: 10ml peripheral blood

TAT：10 working days

Results readout: MTB (molecular tumor burden)
Sampling time: